Position
Squarepoint Ops LLC in Avalo Therapeutics, Inc.
Back to the book · All holders of AVTX
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$132K$18.16 → $14.93
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 40.9K | $741.9K | — | — | — | 0.0% |
| Q1 2026 | 81.3K | $1.21M | $14.93 | −$132K | $603.6K | 0.0% |